Literature DB >> 22585211

Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.

C Garrigós1, O Murillo, J Lora-Tamayo, R Verdaguer, F Tubau, C Cabellos, J Cabo, J Ariza.   

Abstract

Despite the use of daptomycin alone at high doses (greater than 6 mg/kg of body weight/day) against difficult-to-treat infections, clinical failures and resistance appeared. Recently, the combination daptomycin-cloxacillin showed enhanced efficacy in clearing bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA). The aim of this study was to evaluate the efficacy of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg/day in humans, respectively) in combination with cloxacillin in a rat tissue cage infection model by MRSA and to compare its efficacy to that of daptomycin-rifampin. We used MRSA strain ATCC BAA-39. In the log- and stationary-phase kill curves, daptomycin-cloxacillin improved the bactericidal activity of daptomycin, especially in log phase. For in vivo studies, therapy was administered intraperitoneally for 7 days with daptomycin at 100 mg/kg/day and 45/mg/kg/day (daptomycin 100 and daptomycin 45), daptomycin 100-cloxacillin at 200 mg/kg/12 h, daptomycin 45-cloxacillin, and daptomycin 100-rifampin at 25 mg/kg/12 h. Daptomycin-rifampin was the best therapy (P < 0.05). Daptomycin 45 was the least effective treatment and did not protect against the emergence of resistant strains. There were no differences between the two dosages of daptomycin plus cloxacillin in any situation, and both protected against resistance. The overall effect of the addition of cloxacillin to daptomycin was a significantly greater cure rate (against adhered bacteria) than that for daptomycin alone. In conclusion, daptomycin-cloxacillin enhanced modestly the in vivo efficacy of daptomycin alone against foreign-body infection by MRSA and was less effective than daptomycin plus rifampin. The benefits of adding cloxacillin to daptomycin should be especially evaluated against infections by rifampin-resistant MRSA and for protection against the emergence of daptomycin nonsusceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585211      PMCID: PMC3393403          DOI: 10.1128/AAC.00127-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.

Authors:  A Trampuz; M Wenk; Z Rajacic; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 3.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

4.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Methicillin-susceptible Staphylococcus aureus clone related to the early pandemic phage type 80/81 causing an outbreak among residents of three occupational centres in Barcelona, Spain.

Authors:  O Gasch; A Hornero; M A Domínguez; A Fernández; C Suárez; S Gómez; M Camoez; J Linares; J Ariza; M Pujol
Journal:  Clin Microbiol Infect       Date:  2011-10-04       Impact factor: 8.067

6.  Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections.

Authors:  A F Widmer; R Frei; Z Rajacic; W Zimmerli
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

7.  Pathogenesis of foreign body infection: description and characteristics of an animal model.

Authors:  W Zimmerli; F A Waldvogel; P Vaudaux; U E Nydegger
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

8.  Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.

Authors:  Kenneth H Rand; Herbert J Houck
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus.

Authors:  W Zimmerli; R Frei; A F Widmer; Z Rajacic
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

10.  Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials.

Authors:  C Chuard; J C Lucet; P Rohner; M Herrmann; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

View more
  8 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

2.  Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  Cristina El Haj; Oscar Murillo; Alba Ribera; Mireia Vivas; Dolors Garcia-Somoza; Fe Tubau; Javier Cabo; Javier Ariza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Authors:  Kimberly C Claeys; Jordan R Smith; Anthony M Casapao; Ryan P Mynatt; Lisa Avery; Anjali Shroff; Deborah Yamamura; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

4.  Caprine abscess model of tulathromycin concentrations in interstitial fluid from tissue chambers inoculated with Corynebacterium pseudotuberculosis following subcutaneous or intrachamber administration.

Authors:  K E Washburn; V R Fajt; S D Lawhon; L G Adams; L A Tell; W T Bissett
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

5.  Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

Authors:  A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

6.  Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; J Lora-Tamayo; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

7.  A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains.

Authors:  Yi-Chien Lee; Pao-Yu Chen; Jann-Tay Wang; Shan-Chwen Chang
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-06       Impact factor: 2.483

8.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.